Longeveron (LGVN) Current Leases (2022 - 2026)
Longeveron (LGVN) recorded quarterly Current Leases of $688000.0 in Q1 2026, up 5.04% quarter-over-quarter from $655000.0 in Q4 2025, and up 9.03% on a YoY basis from $631000.0 in Q1 2025.
Longeveron (LGVN) Current Leases (2022 - 2026) Analysis & Trends
Longeveron's Current Leases history runs 5 years deep, the most recent figure standing at $688000.0 for Q1 2026.
- In Q1 2026, Current Leases rose 9.03% year-over-year to $688000.0; the TTM figure through Mar 2026 stood at $688000.0 (up 9.03% YoY), while the FY2025 annual figure was $655000.0, up 5.14% from the prior year.
- Current Leases was $688000.0 for Q1 2026 at Longeveron, up from $655000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $688000.0 in Q1 2026 to a low of $564000.0 in Q4 2022.
- Historically, Current Leases has averaged $624090.9 across 5 years, with a median of $623000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Current Leases grew 4.99% in 2025, then increased 9.03% in 2026.
- A 5-year view of Current Leases shows it stood at $564000.0 in 2022, then advanced by 5.14% to $593000.0 in 2023, then advanced by 5.06% to $623000.0 in 2024, then advanced by 5.14% to $655000.0 in 2025, then increased by 5.04% to $688000.0 in 2026.
- The last three Current Leases figures came in at $688000.0 (Q1 2026), $655000.0 (Q4 2025), and $647000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 688,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 688,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 647,000.00 |
| Jun 30, 2025 | 639,000.00 |
| Mar 31, 2025 | 631,000.00 |
| Dec 31, 2024 | 623,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 608,000.00 |
| Mar 31, 2024 | 601,000.00 |
| Dec 31, 2023 | 593,000.00 |
| Dec 31, 2022 | 564,000.00 |